From Name

From Email

To Name

To Email

Message

GBT to request Oxbryta treat children starting at age 4

from Sickle Cell Disease News

GBT to request Oxbryta treat children starting at age 4 Sickle Cell Disease News Global Blood Therapeutics (GBT) will ask the U.S. Food and Drug Administration (FDA) to allow children with sickle cell disease, ages 4 to 11, to also be treated with Oxbryta (voxelotor). The company announced plans to file an application requesting extended approval after a Type B meeting with FDA officials. READ MORE

more